| Distribution | Full List | Categories |
| by Country | by Vaccine |
| updated 6h ago |
doses inoculated as population % |
2-dose immunization at current speed |
|||||
| TOTAL | LAST 7 days |
NOW | 30% | 50% | 70% | ||
| Gibraltar |
93.9% 31,631 |
15.6% 5,252 |
37.8% | Feb 2021 |
Mar 2021 |
Mar 2021 |
|
| Pfizer/BioNTech | |||||||
| Israel |
88.8% 7,683,753 |
10.2% 884,325 |
36.3% | Feb 2021 |
Mar 2021 |
Apr 2021 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Seychelles |
66.7% 65,576 |
7.4% 7,327 |
22.0% | Feb 2021 |
Mar 2021 |
May 2021 |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | |||||||
| United Arab Emirates |
57.3% 5,668,264 |
4.8% 469,539 |
22.1% | Mar 2021 |
Apr 2021 |
Jun 2021 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | |||||||
| Falkland Islands |
43.5% 1,515 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Cayman Islands |
30.3% 19,938 |
4.3% 2,797 |
11.7% | Apr 2021 |
Jun 2021 |
Aug 2021 |
|
| Pfizer/BioNTech | |||||||
| Guernsey |
28.8% 19,284 |
6.2% 4,149 |
8.0% | Apr 2021 |
May 2021 |
Jun 2021 |
|
| Pfizer/BioNTech | |||||||
| United Kingdom |
27.3% 18,558,969 |
3.6% 2,436,697 |
0.9% | May 2021 |
Jul 2021 |
Oct 2021 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Jersey |
25.7% 25,952 |
4.9% 4,945 |
3.2% | Apr 2021 |
Jun 2021 |
Aug 2021 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Isle of Man |
21.2% 18,041 |
4.4% 3,769 |
5.8% | Apr 2021 |
Jun 2021 |
Sep 2021 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Bermuda |
21.1% 13,155 |
5.1% 3,158 |
2.6% | Apr 2021 |
Jun 2021 |
Aug 2021 |
|
| Pfizer/BioNTech | |||||||
| United States |
19.6% 65,032,083 |
3.0% 9,811,719 |
6.0% | Jun 2021 |
Sep 2021 |
Dec 2021 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Anguilla |
18.4% 2,762 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Turks and Caicos Islands |
16.6% 6,433 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Bahrain |
16.5% 281,425 |
1.7% 28,435 |
0.0% | Sep 2021 |
Feb 2022 |
Jul 2022 |
|
| Pfizer/BioNTech, Sinopharm/Beijing | |||||||
| Chile |
16.2% 3,092,526 |
3.6% 688,517 |
0.3% | May 2021 |
Aug 2021 |
Oct 2021 |
|
| Pfizer/BioNTech, Sinovac | |||||||
| Maldives |
15.8% 85,110 |
6.5% 35,063 |
0.0% | Apr 2021 |
May 2021 |
Jul 2021 |
|
| Oxford/AstraZeneca | |||||||
| Malta |
15.0% 66,334 |
2.9% 12,687 |
4.8% | Jun 2021 |
Sep 2021 |
Dec 2021 |
|
| Pfizer/BioNTech | |||||||
| Serbia |
14.5% 987,000 |
6.5% 442,791 |
2.7% | Apr 2021 |
Jun 2021 |
Jul 2021 |
|
| Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | |||||||
| Faeroe Islands |
12.8% 6,259 |
1.0% 487 |
4.3% | Jan 2022 |
Nov 2022 |
Aug 2023 |
|
| Pfizer/BioNTech | |||||||
| Denmark |
8.8% 511,087 |
1.5% 88,801 |
3.0% | Oct 2021 |
Apr 2022 |
Oct 2022 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Turkey |
8.6% 7,289,498 |
3.2% 2,658,714 |
1.4% | Jun 2021 |
Sep 2021 |
Dec 2021 |
|
| Sinovac | |||||||
| Iceland |
8.2% 27,933 |
2.3% 7,902 |
3.1% | Aug 2021 |
Dec 2021 |
Mar 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Romania |
7.5% 1,438,433 |
1.2% 241,344 |
3.1% | Dec 2021 |
Jul 2022 |
Mar 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Lithuania |
7.4% 202,733 |
1.6% 43,986 |
2.6% | Oct 2021 |
Apr 2022 |
Sep 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Greece |
7.3% 762,624 |
1.8% 186,858 |
2.5% | Sep 2021 |
Feb 2022 |
Aug 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Poland |
7.3% 2,759,436 |
1.6% 600,290 |
2.5% | Oct 2021 |
Apr 2022 |
Oct 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Norway |
7.2% 392,858 |
1.6% 84,579 |
1.8% | Oct 2021 |
Apr 2022 |
Oct 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Slovakia |
7.2% 394,790 |
1.3% 71,683 |
2.0% | Dec 2021 |
Jul 2022 |
Feb 2023 |
|
| Pfizer/BioNTech | |||||||
| Morocco |
7.2% 2,667,091 |
2.1% 762,922 |
0.1% | Aug 2021 |
Jan 2022 |
May 2022 |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | |||||||
| Ireland |
7.1% 350,322 |
1.7% 81,771 |
2.6% | Oct 2021 |
Mar 2022 |
Sep 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Hungary |
7.0% 679,850 |
2.0% 196,099 |
2.2% | Sep 2021 |
Jan 2022 |
Jun 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | |||||||
| Slovenia |
7.0% 145,141 |
1.2% 24,767 |
2.4% | Jan 2022 |
Aug 2022 |
Apr 2023 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Estonia |
6.9% 91,785 |
1.7% 22,472 |
2.1% | Oct 2021 |
Mar 2022 |
Aug 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Portugal |
6.8% 694,297 |
1.5% 154,511 |
2.5% | Nov 2021 |
May 2022 |
Nov 2022 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Spain |
6.8% 3,165,191 |
1.2% 540,679 |
2.6% | Jan 2022 |
Sep 2022 |
May 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Barbados |
6.6% 19,089 |
5.1% 14,599 |
0.0% | May 2021 |
Jul 2021 |
Sep 2021 |
|
| Oxford/AstraZeneca | |||||||
| Finland |
6.6% 363,938 |
1.6% 87,469 |
1.4% | Oct 2021 |
Apr 2022 |
Oct 2022 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Cyprus |
6.5% 56,791 |
1.4% 12,362 |
2.2% | Nov 2021 |
Jun 2022 |
Dec 2022 |
|
| Pfizer/BioNTech | |||||||
| Germany |
6.4% 5,373,222 |
1.1% 921,935 |
2.2% | Feb 2022 |
Oct 2022 |
Jun 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Sweden |
6.4% 645,261 |
1.0% 104,704 |
2.2% | Feb 2022 |
Nov 2022 |
Aug 2023 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Singapore |
6.2% 360,000 |
1.6% 91,000 |
1.9% | Oct 2021 |
Apr 2022 |
Oct 2022 |
|
| Pfizer/BioNTech | |||||||
| Italy |
6.1% 3,702,079 |
0.9% 554,172 |
2.2% | Apr 2022 |
Feb 2023 |
Dec 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Monaco |
6.1% 2,400 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Belgium |
5.9% 688,160 |
0.7% 83,680 |
2.3% | Aug 2022 |
Aug 2023 |
Sep 2024 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| France |
5.9% 3,838,375 |
1.3% 823,402 |
1.9% | Dec 2021 |
Aug 2022 |
Mar 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Austria |
5.8% 519,338 |
1.3% 116,352 |
2.2% | Dec 2021 |
Jul 2022 |
Feb 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Czechia |
5.4% 581,542 |
0.9% 91,489 |
2.1% | May 2022 |
Apr 2023 |
Mar 2024 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Luxembourg |
5.1% 31,926 |
1.3% 7,902 |
1.3% | Dec 2021 |
Aug 2022 |
Mar 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Netherlands |
4.9% 835,554 |
1.2% 212,015 |
0.0% | Jan 2022 |
Aug 2022 |
Apr 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Qatar |
4.9% 140,000 |
1.0% 30,000 |
0.0% | Mar 2022 |
Nov 2022 |
Aug 2023 |
|
| Pfizer/BioNTech | |||||||
| Liechtenstein |
4.8% 1,812 |
1.7% 647 |
0.0% | Oct 2021 |
Mar 2022 |
Sep 2022 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Greenland |
4.6% 2,584 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Canada |
4.2% 1,590,281 |
0.8% 283,497 |
0.0% | Aug 2022 |
Aug 2023 |
Aug 2024 |
|
| Moderna, Pfizer/BioNTech | |||||||
| Kuwait |
4.1% 175,000 |
1.1% 49,000 |
0.9% | Feb 2022 |
Oct 2022 |
Jun 2023 |
|
| Pfizer/BioNTech | |||||||
| Croatia |
4.1% 166,146 |
1.1% 45,543 |
1.4% | Feb 2022 |
Oct 2022 |
Jul 2023 |
|
| Pfizer/BioNTech | |||||||
| Brazil |
3.4% 7,297,061 |
0.8% 1,687,124 |
0.6% | Jul 2022 |
Jun 2023 |
Jun 2024 |
|
| Oxford/AstraZeneca, Sinovac | |||||||
| China |
2.8% 40,520,000 |
0.9% 12,848,889 |
0.0% | May 2022 |
Mar 2023 |
Feb 2024 |
|
| Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac | |||||||
| Andorra |
2.8% 2,141 |
0.7% 519 |
0.0% | Oct 2022 |
Dec 2023 |
Jan 2025 |
|
| Pfizer/BioNTech | |||||||
| WORLD |
2.8% 216,167,273 |
0.4% 31,336,132 |
0.6% | Nov 2023 |
Oct 2025 |
Sep 2027 |
|
| Russia |
2.7% 3,900,000 |
0.5% 725,000 |
1.2% | May 2023 |
Nov 2024 |
Jun 2026 |
|
| Sputnik V | |||||||
| Latvia |
2.6% 49,834 |
0.5% 10,204 |
0.9% | Mar 2023 |
Aug 2024 |
Jan 2026 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Bulgaria |
2.1% 148,226 |
1.0% 66,888 |
0.4% | Apr 2022 |
Feb 2023 |
Nov 2023 |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Costa Rica |
2.0% 101,183 |
0.1% 4,235 |
0.9% | Jul 2034 |
Sep 2043 |
Dec 2052 |
|
| Pfizer/BioNTech | |||||||
| Sri Lanka |
1.7% 366,907 |
0.8% 170,744 |
0.0% | Jul 2022 |
Jul 2023 |
Jun 2024 |
|
| Oxford/AstraZeneca | |||||||
| Argentina |
1.6% 746,615 |
0.3% 135,446 |
0.6% | Nov 2024 |
Jun 2027 |
Jan 2030 |
|
| Sputnik V | |||||||
| Bangladesh |
1.5% 2,491,053 |
0.7% 1,131,440 |
0.0% | Oct 2022 |
Nov 2023 |
Jan 2025 |
|
| Oxford/AstraZeneca | |||||||
| Saudi Arabia |
1.4% 501,710 |
0.2% 57,245 |
0.0% | Dec 2027 |
Aug 2032 |
Apr 2037 |
|
| Pfizer/BioNTech | |||||||
| Mexico |
1.4% 1,801,156 |
0.7% 885,773 |
0.4% | Oct 2022 |
Nov 2023 |
Jan 2025 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| Panama |
1.4% 60,088 |
1.1% 47,647 |
0.0% | Mar 2022 |
Nov 2022 |
Jul 2023 |
|
| Pfizer/BioNTech | |||||||
| Nepal |
1.4% 402,264 |
0.4% 106,652 |
0.0% | Mar 2024 |
Apr 2026 |
May 2028 |
|
| Oxford/AstraZeneca | |||||||
| Oman |
1.3% 67,660 |
0.2% 10,813 |
0.4% | Jun 2026 |
Feb 2030 |
Sep 2033 |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | |||||||
| India |
0.9% 11,907,392 |
0.2% 3,050,051 |
0.1% | Apr 2026 |
Oct 2029 |
Mar 2033 |
|
| Covaxin, Oxford/AstraZeneca | |||||||
| Indonesia |
0.8% 2,059,871 |
0.2% 401,761 |
0.3% | Nov 2028 |
Feb 2034 |
May 2039 |
|
| Sinovac | |||||||
| Azerbaijan |
0.6% 65,000 |
|
0.0% | ||||
| Oxford/AstraZeneca, Sputnik V | |||||||
| Peru |
0.6% 204,046 |
0.3% 94,548 |
0.0% | Feb 2025 |
Oct 2027 |
Jun 2030 |
|
| Sinopharm/Beijing | |||||||
| Mauritius |
0.3% 3,843 |
0.1% 1,591 |
0.0% | Apr 2030 |
Jun 2036 |
Jul 2042 |
|
| Oxford/AstraZeneca | |||||||
| Lebanon |
0.3% 19,394 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Guyana |
0.2% 1,852 |
0.2% 1,184 |
0.0% | Oct 2028 |
Nov 2033 |
Dec 2038 |
|
| Oxford/AstraZeneca | |||||||
| Belarus |
0.2% 20,944 |
|
0.0% | ||||
| Sputnik V | |||||||
| Myanmar |
0.2% 103,142 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Algeria |
0.2% 75,000 |
0.1% 26,240 |
0.0% | Apr 2040 |
Feb 2053 |
Dec 2065 |
|
| Sputnik V | |||||||
| Albania |
0.2% 4,177 |
0.1% 2,135 |
0.0% | Aug 2036 |
Dec 2046 |
Apr 2057 |
|
| Pfizer/BioNTech | |||||||
| Dominican Republic |
0.1% 14,264 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Colombia |
0.1% 48,150 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Bolivia |
0.1% 10,167 |
0.1% 5,781 |
0.0% | May 2044 |
Oct 2059 |
Apr 2075 |
|
| Sputnik V | |||||||
| El Salvador |
0.1% 6,000 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Ecuador |
0.1% 8,190 |
0.0% 1,056 |
0.0% | Feb 2213 |
Mar 2341 |
Apr 2469 |
|
| Pfizer/BioNTech | |||||||
| South Africa |
0.1% 32,315 |
|
0.1% | ||||
| Johnson&Johnson | |||||||
| Zimbabwe |
0.0% 4,041 |
|
0.0% | ||||
| Sinopharm/Beijing | |||||||
| Pakistan |
0.0% 72,882 |
0.0% 29,053 |
0.0% | Jul 2108 |
Oct 2166 |
Feb 2225 |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | |||||||
| Trinidad and Tobago |
0.0% 440 |
|
0.0% | ||||
| Oxford/AstraZeneca | |||||||
| Cambodia |
0.0% 4,609 |
0.0% 2,424 |
0.0% | Jun 2100 |
Apr 2153 |
Mar 2206 |
|
| Sinopharm/Beijing | |||||||
| Iran |
0.0% 10,000 |
0.0% 6,125 |
0.0% | Oct 2178 |
Dec 2283 |
Jan 2389 |
|
| Sputnik V | |||||||
| Australia |
0.0% 2,879 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Japan |
0.0% 11,934 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Egypt |
0.0% 1,315 |
|
0.0% | ||||
| Sinopharm/Beijing | |||||||
| New Zealand |
0.0% 100 |
|
0.0% | ||||
| Pfizer/BioNTech | |||||||
| Guinea |
0.0% 25 |
|
% | ||||